DCF Tool

HOLX

Hologic, Inc. – Irradiation Apparatus Manufacturing
driven by our ethos, the science of sure, we’re a diverse, dedicated, creative team that develops, markets and services some of the most innovative and accurate diagnostic imaging systems and surgical products on the planet. while we’re focused and passionate about our work, we never forget that what we’re really doing is giving people greater confidence and peace of mind in their diagnosis—enabling healthier lives, everywhere, every day. connect with us at hologic.com, on facebook at facebook.com/hologicjobs, and on twitter @hologic_jobs.
Analysis Results
Intrinsic Value $176.32
Latest Price $73.83
Relative Value 58% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Billions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 7.8%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 6.1%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 7.8%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2024 1.46 1.37
2025 1.57 1.4
2026 1.69 1.42
2027 1.83 1.44
2028 1.97 1.47
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 48.9 billion. This corresponds to a present value of 34.3 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 7.09 billion. Adding in the terminal value gives a total present value of 41.4 billion.

There are presently 235.0 million outstanding shares, so the intrinsic value per share is 176.32.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 4,184,500,000
Current Cash 2,722,500,000
Current Liabilities 1,207,300,000
Current Debt 290,100,000
Non-Cash Working Capital (NCWC) 544,800,000
Change in NCWC -58,200,000
EBIT 941,000,000
Tax Provision 220,100,000
Depreciation and Amortization 323,400,000
Capital Expenditure -91,800,000
Unlevered Free Cash Flow 808,063,511
Current Assets 3,862,000,000
Current Cash 2,339,500,000
Current Liabilities 937,700,000
Current Debt 18,200,000
Non-Cash Working Capital (NCWC) 603,000,000
Change in NCWC -385,300,000
EBIT 1,648,200,000
Tax Provision 286,200,000
Depreciation and Amortization 430,100,000
Capital Expenditure -70,600,000
Unlevered Free Cash Flow 1,325,387,759
Current Assets 3,168,700,000
Current Cash 1,170,300,000
Current Liabilities 1,326,800,000
Current Debt 316,700,000
Non-Cash Working Capital (NCWC) 988,300,000
Change in NCWC 379,500,000
EBIT 2,482,900,000
Tax Provision 491,400,000
Depreciation and Amortization 406,900,000
Capital Expenditure -103,300,000
Unlevered Free Cash Flow 2,649,250,578
Current Assets 2,222,300,000
Current Cash 701,000,000
Current Liabilities 1,239,300,000
Current Debt 326,800,000
Non-Cash Working Capital (NCWC) 608,800,000
Change in NCWC 322,700,000
EBIT 1,150,500,000
Tax Provision -108,600,000
Depreciation and Amortization 376,000,000
Capital Expenditure -98,300,000
Unlevered Free Cash Flow 1,750,900,000
Current Assets 1,630,400,000
Current Cash 590,700,000
Current Liabilities 1,026,800,000
Current Debt 273,200,000
Non-Cash Working Capital (NCWC) 286,100,000
Change in NCWC 30,800,000
EBIT 564,900,000
Tax Provision -54,100,000
Depreciation and Amortization 463,100,000
Capital Expenditure -57,000,000
Unlevered Free Cash Flow 1,001,800,000
Current Assets 1,723,200,000
Current Cash 666,700,000
Current Liabilities 1,402,600,000
Current Debt 601,400,000
Non-Cash Working Capital (NCWC) 255,300,000
Change in NCWC 30,400,000
EBIT 508,000,000
Tax Provision -307,300,000
Depreciation and Amortization 480,300,000
Capital Expenditure -58,400,000
Unlevered Free Cash Flow 960,300,000
Current Assets 1,478,600,000
Current Cash 540,600,000
Current Liabilities 1,865,500,000
Current Debt 1,152,400,000
Non-Cash Working Capital (NCWC) 224,900,000
Change in NCWC 52,600,000
EBIT 483,800,000
Tax Provision 475,000,000
Depreciation and Amortization 449,200,000
Capital Expenditure -57,800,000
Unlevered Free Cash Flow 741,042,584
Current Assets 1,326,600,000
Current Cash 548,400,000
Current Liabilities 901,900,000
Current Debt 296,000,000
Non-Cash Working Capital (NCWC) 172,300,000
Change in NCWC -50,600,000
EBIT 559,100,000
Tax Provision 84,500,000
Depreciation and Amortization 465,400,000
Capital Expenditure -47,300,000
Unlevered Free Cash Flow 812,841,391
Current Assets 1,266,400,000
Current Cash 491,300,000
Current Liabilities 944,000,000
Current Debt 391,800,000
Non-Cash Working Capital (NCWC) 222,900,000
Change in NCWC -101,700,000
EBIT 483,600,000
Tax Provision 45,600,000
Depreciation and Amortization 491,400
Capital Expenditure -48,100
Unlevered Free Cash Flow 257,895,444
Current Assets 1,565,800,000
Current Cash 736,100,000
Current Liabilities 619,600,000
Current Debt 114,500,000
Non-Cash Working Capital (NCWC) 324,600,000
Change in NCWC 47,541,000
EBIT 363,600,000
Tax Provision 30,800,000
Depreciation and Amortization 523,200,000
Capital Expenditure -44,300,000
Unlevered Free Cash Flow 657,216,051
Current Assets 1,624,143,000
Current Cash 822,490,000
Current Liabilities 1,088,406,000
Current Debt 563,812,000
Non-Cash Working Capital (NCWC) 277,059,000
Change in NCWC -128,611,000
EBIT 203,032,000
Tax Provision -20,123,000
Depreciation and Amortization 516,010,000
Capital Expenditure -90,130,000
Unlevered Free Cash Flow 500,301,000
Current Assets 1,563,014,000
Current Cash 560,430,000
Current Liabilities 661,349,000
Current Debt 64,435,000
Non-Cash Working Capital (NCWC) 405,670,000
Change in NCWC 284,552,000
EBIT 168,052,000
Tax Provision 11,973,000
Depreciation and Amortization 345,751,000
Capital Expenditure -33,149,000
Unlevered Free Cash Flow 765,206,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.